References
- Standards of medical care in diabetes – 2018. Diabetes Care. 2018;41(Suppl 1):S73–S85.
- Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin. 2011;27(5):887–895.
- Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–1747.
- Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci. 2015;11(3):463–482.
- Stout MB, Justice JN, Nicklas BJ, et al. Physiological aging: links among adipose tissue dysfunction, diabetes, and frailty. Physiology. 2017;32(1):9–19.
- Brusko CSA, Taylor AD, Jackson JA, et al. Clinical challenges with concentrated insulins: setting the record straight. Diabetes Spectr. 2017;30(4):229–232.
- Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.
- Heinemann L, Beals JM, Malone J, et al. Concentrated insulins: history and critical reappraisal. J Diabetes. 2019;11(4):292–300.
- Schloot NC, Hood RC, Corrigan SM, et al. Concentrated insulins in current clinical practice. Diabetes Res Clin Pract. 2019;148:93–101.
- de la Pena A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev. 2016;5(1):69–75.
- Ovalle F, Segal AR, Anderson JE, et al. Understanding concentrated insulins: a systematic review of randomized controlled trials. Curr Med Res Opin. 2017;34(6):1029–1043.
- Rees TM, Lennartz AH, Ignaut DA. A comparison of glide force characteristics between 2 prefilled insulin lispro pens. J Diabetes Sci Technol. 2015;9(2):316–319.
- Wang T, Conrad KA, van Brunt K, et al. Attributes influencing insulin pen preference among caregivers and patients with diabetes who require greater than 20 units of mealtime insulin. J Diabetes Sci Technol. 2016;10(4):923–931.
- Summary of product characteristics. Humalog 200 units/ml KwikPen, solution for injection in prefilled pen [updated 2018 Jun 29. cited 2019 Mar 1]. Available from: https://www.medicines.org.uk/emc/product/3725/smpc.
- Rathmann W, Bongaerts B, Carius HJ, et al. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56(10):459–466.
- Basson M, Ntais D, Ayyub R, et al. The cost-effectiveness of dulaglutide 1.5mg versus exenatide QW for the treatment of patients with type 2 diabetes mellitus in France. Diabetes Ther. 2018;9(1):13–25.
- Kostev K, Jacob L. Association between depression and persistence with oral antihyperglycemic drugs in type 2 diabetes mellitus patients in Germany. Psychiatry Res. 2018;261:90–93.
- Kostev K, Rockel T, Jacob L. Prescription patterns and disease control in type 2 diabetes mellitus patients in nursing home and home care settings: a retrospective analysis in Germany. J Diabetes Sci Technol. 2018;12(1):136–139.
- Grant RW, Ashburner JM, Hong CS, et al. Defining patient complexity from the primary care physician's perspective: a cohort study. Ann Intern Med. 2011;155(12):797–804.
- Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3–15.
- International Diabetes Federation Diabetes Atlas [Internet]. International Diabetes Federation; 2017. [cited 2018 Jan 2]. Available from: http://www.diabetesatlas.org/resources/2017-atlas.html.
- Bohn B, Kerner W, Seufert J, et al. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract. 2016;115:31–38.
- Blak BT, Smith HT, Hards M, et al. A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. Diabet Med. 2012;29(8):e191-198–e198.